Loading clinical trials...

Construction of a Database for TMA | Clinical Trials | Clareo Health

RECRUITING

Construction of a Database for TMA

Construction of a Database for Thrombotic Microangiopathy

NCT05634928•The First Affiliated Hospital of Soochow University

Summary

Information about patients was collected by reviewing the Hitech case system and telephone and outpatient follow-up, and the case database was constructed by Epidata software. The sample size is expected to be 200 cases, the participating hospital is the First Affiliated Hospital of Soochow University, and the study time frame is from Dec 1, 2022, to Nov 31, 2027. The observation indexes of the study include the basic information of patients' age and gender and the clinical-related data of thrombotic microangiopathy.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•The patient has elevated lactate dehydrogenase to more than twice the baseline value, platelets less than 20 or decreased by more than 50% within 24 hours, and more than 2% of schistocytes visible on a peripheral blood smear. Alternatively, pathological sections show extensive micro thrombosis.

Exclusion Criteria

•The investigator considers the subject unable or unwilling to cooperate with the study procedures.

Locations (1)

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Key Dates

Start Date

December 1, 2022

Primary Completion Date

November 30, 2027

Completion Date

November 30, 2028

Last Updated

December 2, 2022

Enrollment

500

ESTIMATED participants

Conditions

Thrombotic Microangiopathies

Interventions

collection data

OTHER

Contacts

Yue Han, PhD

CONTACT

+86 18913091817 hanyue@suda.edu.cn

Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura

NCT06291025

Thrombotic Microangiopathies

View study

RECRUITING

Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy

NCT06102694

Thrombotic MicroangiopathiesHematopoietic Stem Cell Transplantation

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 2, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Construction of a Database for TMA

Inclusion Criteria

Exclusion Criteria

Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura

Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

TGD001 Treatment in Thrombotic Microangiopathies

Defibrotide TMA Prophylaxis Pilot Trial